A commentary examines when stopping a clinical trial early is ethically justified and how premature termination can affect participants and medical research.
The Lysenkoism comparison
The article uses “Lysenkoism 2.0” to describe what it sees as political control over federally funded science. The name refers to Trofim Lysenko, a Soviet agricultural scientist who rejected Mendelian genetics and Darwinian natural selection in favor of ideas resembling Lamarckism. Stalin backed Lysenko because his theories fit the regime’s ideology, not because the evidence supported them.
The consequences were severe. Lysenko’s methods damaged Soviet agriculture for decades, with crop yields falling and famines worsening from the 1930s into the early 1960s. His influence declined after Stalin’s death, and he was eventually removed from power. Scientists who challenged him faced ostracism, dismissal, imprisonment, and, in some cases, execution. The term “Lysenkoism” now describes science subordinated to ideology rather than evidence, experiments, and data; Soviet agricultural research took decades to recover.
The author argues that the current US situation is broader in reach, though scientists aren’t being executed for opposing Health and Human Services Secretary Robert F. Kennedy Jr., a longtime antivaccine activist, or his allies. The examples cited include introducing antivaccine pseudoscience into NIH programs, changing NIH peer review, calls to make NIH the “research arm of MAHA,” and appointing political operatives to steer grants toward administration priorities. The author also points to space science, citing a report that astrophysicist Holley Bockelmann is leaving the US for Denmark amid the administration’s actions.
That’s the wider argument; the immediate concern is the termination of NIH-funded trials for what the author calls explicitly ideological reasons. The piece says no previous administration, including conservative Republican ones, has canceled large numbers of NIH research grants on this scale or for ideological reasons. It compares the current actions with George W. Bush’s restrictions on embryonic stem cell research, which it considers limited by comparison, and criticizes scientists who revisit claims of being “canceled” during the pandemic while overlooking what it describes as a larger threat to US science. The cited discussion of those claims is here.
When should a trial stop?
Early termination isn’t automatically improper. The commentary by Dal-Re, Bierer, and Caplan begins with the Declaration of Helsinki, the central ethical framework cited here for research involving human participants. Its governing principle is that participants’ rights and interests come before other considerations. Trials may stop early for scientific reasons, but those reasons should be set out in advance, approved by an institutional review board or research ethics committee, and assessed with the trial’s Data and Safety Monitoring Board. The authors say an early stop is acceptable when its scientific basis is rigorously justified, clearly communicated, and paired with plans for participant care and data stewardship.
A foundational ethical principle guiding termination of trials since the 1975 revision of the Declaration of Helsinki, is that the rights and interests of clinical trial participants must take precedence over all other considerations.
The early termination of trials can be due to scientific motives. When termination is contemplated for scientific reasons, investigators ought to have prospectively established stopping rules that are reviewed and approved by the relevant institutional review board/research ethics committee. Fulfillment of these rules is the only acceptable basis for terminating a trial before completing its planned sample size or follow-up. The role of a trial’s Data and Safety Monitoring Board is critical when the conditions for trial discontinuation are met—i.e., when scientific grounds are invoked. When the scientific rationale for termination is rigorously justified, transparently communicated, and accompanied by appropriate plans for participant care and data stewardship, the decision is generally accepted by both the scientific and bioethical communities.
Here’s the tension: protecting participants can require stopping a trial before it reaches its planned size. The author criticizes what he calls “methodolatry”—treating randomized controlled trials as the only valid form of clinical evidence, while setting aside ethical obligations. He cites arguments that vaccine trials are invalid without a saline-only placebo, a position discussed in this article, and the selective rejection of imperfect trials when their results conflict with a critic’s beliefs.
Most trials include planned interim analyses before they enroll every participant. If those analyses show that one group is clearly doing worse, continuing to assign people to it can no longer be justified. The experimental treatment might be outperforming the comparison group, or it might be causing harm or falling short of standard care. Either way, the key ethical condition—equipoise, genuine uncertainty about which option is better—has ended. That is a scientifically grounded reason to stop. Whether funding cuts meet that standard is the harder question the article sets up.
When stopping a trial is justified—and when it isn’t
Interim analyses can justify ending a clinical trial early when the evidence shows that one treatment arm is producing clearly better outcomes. If an experimental treatment is outperforming a placebo or standard care, participants in the other groups should be offered it promptly to reduce potential harm.
That ethical case is narrow. The commentary’s authors argue that commercial pressures—such as a merger, lost investment, a change in company strategy, or a competitor’s success—usually don’t justify abandoning a trial. Those decisions can break the expectations participants relied on when they consented, upset the balance of risks and benefits, and waste the contribution they made to medical research.
The scale of the problem has grown. A review of 3,145 industry-sponsored Phase 2 and Phase 3 trials terminated between 2013 and 2023 found that early terminations rose from 11% of completed trials in 2013 (209 trials) to 23% in 2023 (435). Commercial reasons accounted for 36.1% of terminations, ahead of lack of efficacy at 23.9% and safety concerns at 5.3%. The pattern matters: business decisions were the most commonly reported reason.
That evidence concerns industry-sponsored studies, which are usually designed to support a company’s application for FDA approval. The NIH funds a smaller share of drug trials, most of which are industry-backed, but federal support also reaches studies companies may have little incentive to pursue: trials of unpatentable natural products, behavioral interventions, and other research that doesn’t promise a marketable drug. That makes the growing use of a different rationale for ending trials especially troubling: political or ideological objections.
Federal cuts and interrupted trials
In early 2025, the Trump administration cut federal research support based on stated policy priorities and reviews prompted by particular terms and topics. NIH and other agencies were affected; USAID was nearly dismantled, and thousands of multiyear contracts in developing countries were canceled. Trials involving cancer, diarrhea, malaria, and HIV were among those stopped.
The authors characterize ideological, political, or policy-based cancellations as a third category of premature termination. The consequences are visible in studies that USAID had supported, including trials of two experimental HIV vaccines, malaria prevention and treatment, and hydration interventions intended to prevent chronic kidney disease among impoverished workers. Those weren’t NIH-funded trials, but the disruption to NIH research has also been substantial.
A study by Patel and colleagues examined NIH-supported clinical trials with active grants terminated between February 28 and August 15, 2025. Of 11,008 trials, 383—3.5%—lost grant funding. At the time, 74,311 participants were in trials marked “active, not recruiting,” meaning they were receiving interventions or being followed. The affected studies most often involved cancer (31%), infectious disease (25%), and reproductive health (13%); behavioral interventions accounted for 46%, drugs 25%, and devices 4%.
That participant count is striking. Pivotal medical-device trials often enroll hundreds of people, not tens of thousands, though enrollment varies by device and regulatory pathway. Here’s the breakdown of affected trials by disease area:
| Disease area | Trials affected |
|---|---:|
| Cancer | 118 |
| Infectious diseases | 97 |
| Reproductive health | 48 |
| Mental health | 47 |
| Metabolic disorders | 21 |
| Cardiovascular disease | 18 |
| Neurological disorders | 11 |
The NIH disputed the study’s findings in a letter from Matthew Memoli, an ally of OMB Director Russell Vought. Some observers, including the author, regard Memoli as the real power behind Jay Bhattacharya, who had been NIH director in title for nearly six months after the study appeared. Memoli said the NIH had repeated and updated the analysis, finding just 28 trials still “associated with terminated grants,” of which 14 were actively enrolling.
That comparison is hard to assess. “Remain associated” may describe a later snapshot, while Patel and colleagues counted grants terminated within a defined period. The NIH letter doesn’t give enough methodological detail to explain how it reproduced or updated the analysis, why its figure was so much lower, or whether its 14 actively enrolling trials are comparable to the paper’s 134 trials recruiting when funding ended. The letter is one page; the methods aren’t there. I don’t find its account convincing.
By proportion, infectious disease research was hit hardest: 14.4% of NIH-funded clinical trials in that area were terminated early. An earlier Association of American Medical Colleges (AAMC) analysis, published in May 2025, found that among grants terminated by then:
- 56% involved HIV/AIDS research.
- 40% focused on mental or behavioral health.
- 18% focused on cancer.
- 16% focused on COVID-19.
- 60% mentioned LGBTQ+ populations.
- 57% mentioned racial or ethnic subpopulations.
- 35% mentioned women.
- 22% mentioned low-income populations.
The distribution raises an obvious question about which research priorities were targeted. The figures don’t answer that question by themselves, but the pattern is difficult to ignore.
Patel and colleagues’ study appeared in November 2025 and covered a period of less than six months. The authors said they couldn’t readily compare it with historical rates because comprehensive historical data on grant terminations aren’t available. They did note that NIH grant terminations were rare before 2025, which matches the author’s experience dating back to the 1990s. Their concern is straightforward: trials need sustained funding to protect participants and keep the research sound. Unexpected funding gaps risk wasted work, compromised data, and failures to meet ethical obligations.
The damage can outlast the cancellation. A trial stopped before it has enough participants, treatment, or follow-up may produce weak results—or data that can’t be used at all. Restarting it may be difficult even if funding returns: universities can’t keep staff without grants, and researchers who leave take experience and institutional knowledge with them. Clinical databases also need ongoing maintenance. Once data entry and updates fall behind, restoring funding doesn’t necessarily restore the lost ground.
The true scale may exceed the Patel study’s count. Trials Tracker, developed by Rob Wagner and Amy Knopf, an associate professor of nursing at Indiana University, aims to document clinical trials affected by NIH award terminations, funding freezes, and delays. It lists thousands of affected grants and hundreds of trials with planned enrollment totaling hundreds of thousands. Those figures need careful handling: the site combines award data from Grant Witness with records from ClinicalTrials.gov, and enrollment figures don’t tell us how many participants were harmed or left without care. Trial records also don’t distinguish people already enrolled from total planned enrollment. Still, the tracker offers a useful estimate of the possible scale of the disruption.
The cost of treating research as a political target
The editorial accompanying Patel and colleagues’ study lays out what funding cancellations waste: investigators’ time, scientific opportunity, federal tax dollars, and the effort participants put into visits, tests, and procedures. Trials that are already underway have accumulated costs. Ending them leaves questions unanswered and can squander that investment, even when the stated aim is to save money.
The more direct injury is to participants. People agree to spend time, accept risks, and undergo procedures in the hope of advancing knowledge. A sudden, scientifically unjustified termination can violate those expectations, interrupt an intervention, or leave people without adequate monitoring for side effects. For some, a trial offered hope after other treatment options had failed. For others, taking part was a way to contribute to future patients. An abrupt cancellation can take both away.
The NIH has been a central institution in U.S. science for eight decades, with broad bipartisan support and some protection from political interference. Its funding has backed major achievements by NIH researchers and by scientists and physicians elsewhere. The author argues that the Trump administration and its HHS secretary have inflicted generational damage by pushing grant decisions toward political appointees and administration priorities—and by treating research funding as a tool to reward allies and punish opponents.
If funding can be withdrawn because a project conflicts with the administration’s views, researchers will have to account for that risk when they recruit participants. As Dal-Ré and colleagues argue, future consent forms may need to spell out the possibility that a trial could end prematurely for political reasons.
Disclosure won’t protect trial participants
Ideological cancellations create a risk that clinical researchers can’t treat as a footnote. Trials may be stopped for political reasons in the United States or elsewhere, so researchers and analysts should recognize ideology as a possible third category of premature termination. Consent documents should explain that a study may end early, what would trigger that decision, what happens next, and how participants’ care and data will be handled.¹¹
But disclosure alone doesn’t resolve the ethical problem. A funder’s interests—whether corporate or governmental—shouldn’t override the rights and welfare of participants.
For NIH-funded researchers, that could mean telling prospective volunteers that a politically opposed administration might cut funding before a study is complete. The practical effect on recruitment is uncertain; adding that risk to consent forms may make participation harder to sell. And the concern reaches beyond any single trial: the author argues that federal science has been badly damaged by an administration pursuing what they call “Lysenkoism 2.0.”
The closing judgment is bleak. An institution built over 80 years, the author says, has been degraded in less than two, and they doubt it will recover its former strength. That forecast is hard to measure now. The immediate point is clearer: when researchers can’t count on a study’s funding lasting through its planned course, participants and scientists alike bear the cost.
Discussion
Sign in to join the discussion.